Literature DB >> 20685165

Therapeutic applications of ribozymes and riboswitches.

Jérôme Mulhbacher1, Patrick St-Pierre, Daniel A Lafontaine.   

Abstract

Therapeutic approaches employing RNA as a tool or as a drug target have recently emerged and have been employed for various applications-ranging from cancer treatment to virus infection. Despite the paucity of its molecular groups compared to proteins, RNA has nevertheless proved to be an excellent choice for researchers who have aspired to develop therapeutic tools. Ribozymes and riboswitches are RNA-based therapeutic tools that are most often employed to knockdown gene expression and to inhibit bacterial infections, respectively. The aim of this review is to summarize recent advances observed in ribozyme- and riboswitch-based therapeutic applications that, in some cases, have reached clinical trials. Crown
Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685165     DOI: 10.1016/j.coph.2010.07.002

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  40 in total

Review 1.  Gene therapy in the cornea: 2005--present.

Authors:  Rajiv R Mohan; Jonathan C K Tovey; Ajay Sharma; Ashish Tandon
Journal:  Prog Retin Eye Res       Date:  2011-09-28       Impact factor: 21.198

Review 2.  Riboswitch structure in the ligand-free state.

Authors:  Joseph A Liberman; Joseph E Wedekind
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-09-28       Impact factor: 9.957

3.  Differential analogue binding by two classes of c-di-GMP riboswitches.

Authors:  Carly A Shanahan; Barbara L Gaffney; Roger A Jones; Scott A Strobel
Journal:  J Am Chem Soc       Date:  2011-09-08       Impact factor: 15.419

Review 4.  RNA-mediated regulation in pathogenic bacteria.

Authors:  Isabelle Caldelari; Yanjie Chao; Pascale Romby; Jörg Vogel
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

5.  Molecular insights into the ligand-controlled organization of the SAM-I riboswitch.

Authors:  Benoit Heppell; Simon Blouin; Anne-Marie Dussault; Jérôme Mulhbacher; Eric Ennifar; J Carlos Penedo; Daniel A Lafontaine
Journal:  Nat Chem Biol       Date:  2011-05-01       Impact factor: 15.040

Review 6.  Biomolecular engineering for nanobio/bionanotechnology.

Authors:  Teruyuki Nagamune
Journal:  Nano Converg       Date:  2017-04-24

7.  One-Pot Production of RNA Nanoparticles via Automated Processing and Self-Assembly.

Authors:  Daniel L Jasinski; Daniel W Binzel; Peixuan Guo
Journal:  ACS Nano       Date:  2019-03-22       Impact factor: 15.881

Review 8.  Structure and function of preQ1 riboswitches.

Authors:  Catherine D Eichhorn; Mijeong Kang; Juli Feigon
Journal:  Biochim Biophys Acta       Date:  2014-05-04

9.  Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers.

Authors:  Farzin Haque; Dan Shu; Yi Shu; Luda S Shlyakhtenko; Piotr G Rychahou; B Mark Evers; Peixuan Guo
Journal:  Nano Today       Date:  2012-08       Impact factor: 20.722

10.  Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.

Authors:  Daniel W Binzel; Yi Shu; Hui Li; Meiyan Sun; Qunshu Zhang; Dan Shu; Bin Guo; Peixuan Guo
Journal:  Mol Ther       Date:  2016-04-29       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.